Opinion/decision on a Paediatric investigation plan (PIP): Onglyza, Saxagliptin, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Endocrinology-Gynaecology-Fertility-Metabolism, PIP number: P/0478/2022

Opinion/decision on a Paediatric investigation plan (PIP): Hepcludex, Bulevirtide, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Infectious diseases, PIP number: P/0270/2022

Opinion/decision on a Paediatric investigation plan (PIP): Cystadrops, Cysteamine hydrochloride, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Ophthalmology, PIP number: P/0019/2022

Opinion/decision on a Paediatric investigation plan (PIP): Triumeq, dolutegravir,abacavir,lamivudine, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Infectious diseases, PIP number: P/0038/2023

Opinion/decision on a Paediatric investigation plan (PIP): Beyfortus, Nirsevimab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Vaccines, PIP number: P/0296/2021

Opinion/decision on a Paediatric investigation plan (PIP): Kisplyx, Lenvatinib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Oncology, PIP number: P/0528/2022

Opinion/decision on a Paediatric investigation plan (PIP): Taltz, ixekizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Dermatology, PIP number: P/0087/2020

Opinion/decision on a Paediatric investigation plan (PIP): Blincyto, blinatumomab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Oncology, PIP number: P/0449/2023

Opinion/decision on a Paediatric investigation plan (PIP): Jakavi, Ruxolitinib (phosphate), decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Oncology, PIP number: P/0527/2021

Opinion/decision on a Paediatric investigation plan (PIP): Jakavi, Ruxolitinib (phosphate), decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Oncology, PIP number: P/0172/2021